Trials / Completed
CompletedNCT00231348
Nefazodone in the Treatment of Social Phobia
Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Emory University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
Detailed description
The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nefazodone |
Timeline
- Completion
- 2000-04-01
- First posted
- 2005-10-04
- Last updated
- 2013-11-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00231348. Inclusion in this directory is not an endorsement.